NCT05474053View on ClinicalTrials.gov

Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 13, 2021

Primary Completion Date

November 28, 2021

Study Completion Date

November 28, 2021

Conditions
Cardiovascular DiseasesAcute Coronary Syndrome
Interventions
DRUG

Ticagrelor 90mg (Brilique)

compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers

DRUG

Ticagrelor 90mg (Ticaloguard)

compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers

Trial Locations (1)

4262004

Faculty of Medicine, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05474053 - Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence | Biotech Hunter | Biotech Hunter